Topic: Medical Science

Malhotra explains that the FDA and the UK's MHRA receive over 50% of their funding from the pharmaceutical industry, leading to a conflict of interest. He recounts his own "blind spot" regarding vaccines and his previous appearances on "Good Morning Britain" to promote their safety. He asserts that prescribed medications are now the third leading cause of death globally due to suppressed side-effect data.

In her final segment, Dr. Lee Merritt advocates for the creation of an "InfoWars for medicine" to allow doctors to share information without censorship. She criticizes the centralization of medical learning under a few top-down guidelines, which she believes has corrupted scientific publishing. Merritt stresses that taking back the language and maintaining local, grassroots connections are the keys to defeating the current biomedical assault.

Dr. McCullough emphasizes that the "golden window" for COVID-19 treatment is the first three days of symptoms. He cites a new paper in the Medical Science Monitor regarding the success of early intervention in preventing hospitalization. He notes a growing number of academic physicians are privately reaching out to support his stance as they witness vaccine failures and injuries firsthand.

Lynn Davenport and Owen Shroyer discuss the lack of public debate regarding vaccine safety and the origins of COVID-19. They reference Dr. Richard Fleming's work regarding gain-of-function research and the characterization of the virus as a bioweapon. Shroyer argues that "trust the science" is a manipulative slogan used to silence doctors who have been bought and paid for by the pharmaceutical industry.

J.B. Handley is featured in a clip from "The Doctors" where he challenges the medical panel on the lack of comprehensive studies regarding the full vaccine schedule and autism. Handley argues that only a fraction of vaccine ingredients have been studied, calling the current consensus "tobacco science." The panel's reaction is characterized as defensive and scripted to protect pharmaceutical interests.